High levels of pre-treatment CXCL13+ T cells are associated with pro-inflammatory macrophage activity and predict favorable responses in patients with triple-negative breast cancer receiving paclitaxel combined with a PD-L1 monoclonal antibody (31). The gene discussed is CXCL13; the disease is triple-negative breast carcinoma.